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Tumor recurrence, metastatic spread and progressive gain of chemo-resistance of advanced cancers are sustained by the presence of
cancer stem cells (CSCs) within the tumor. Targeted therapies with the aim to eradicate these cells are thus highly regarded. However, often
the use of new anti-cancer therapies is hampered by pharmacokinetic demands. Drug delivery through nanoparticles has great potential to
increase efficacy and reduce toxicity and adverse effects. However, its production has to be based on intelligent design. Likewise, we
developed polymeric nanoparticles loaded with Zileuton™, a potent inhibitor of cancer stem cells (CSCs), which was chosen based on high
throughput screening. Its great potential for CSCs treatment was subsequently demonstrated in in vitro and in in vivo CSC fluorescent
models. Encapsulated Zileuton™ reduces amount of CSCs within the tumor and effectively blocks the circulating tumor cells (CTCs) in the
blood stream and metastatic spread.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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cancer stem cells. Nanomedicine: NBM 2020;24:102106, https://doi.org/10.101incurable disease.1 ,2 Particularly aggressive is the Triple
Negative Breast Cancer (TNBC), which does not respond to
current hormonal therapy and medicines targeting HER2
receptors, because of the absence of estrogen−, progesterone
−, and Her2− surface receptors in tumor cells. It has been
suggested that tumor progression and dissemination are
mediated by the presence of specific Cancer Stem Cells
(CSCs) subpopulations within the tumor. CSCs are also
thought to be responsible for cancer relapse and of being
intrinsically resistant to most current treatments. According-
ly, CSCs are thus responsible for many therapeutic failures.-
3–5 Unfortunately, there are no effective treatments yet
targeting CSCs and their metastatic spread to distal organs.ess article under the CC BY-NC-ND license 4.0
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become essential to develop new therapeutic strategies
against CSC to successfully eradicate advanced cancer and
prevent metastasis.
Unfortunately, many prospective drugs do not have
sufficient solubility or adequate pharmacokinetics to reach
good efficacy and toxicity profiles for clinical use. In this
context, specific nano-sized drug delivery systems (nano-
DDS) offer the possibility of converting agents with low
therapeutic profile into forthcoming clinical drug candidates.
Further, nano-encapsulation facilitates the administration of
hydrophobic agents while protecting them during circulation,
lowering the undesired side effects associated with a
systemic, non-controlled distribution of the drug. Nanome-
dicines can also evade Multi Drug Resistant mechanisms
(i.e., MDR channels) and increase drug's intracellular
accumulation, improving the efficacy of the treatment.4 ,6 ,7
We have used two recently characterized fluorescent
breast CSC models to identify by high throughput screening
potential therapeutic target candidates in CSCs.8 ,9 These
models express tdTomato (red fluorescence) under the
control of the CSC specific promoter, ALDH1A1. Thus,
tdTomato fluorescence is detected exclusively in the CSC
subpopulation, while differentiated cancer cells (non-CSCs)
do not express the fluorescent marker. This system allows
not only to segregate CSCs from non-CSCs subpopulations,
but also to monitor the biological performance of CSCs in
situ; before, during and after treatment.8–11 Our data
revealed arachidonate 5-lipoxygenase (5-LO) gene (Alox5)
as a potential therapeutic candidate in breast CSCs.
Recently, ALOX5 was also identified as a critical regulator
of CSCs from Chronic Myeloid Leukemia (CML).12
Moreover, we have recently demonstrated that siRNA
inhibition of Alox5 is able to downregulate the expression
of the gene in vitro and also of decreasing invasion and
malignant transformation of breast CSCs.13
Zileuton™ is a specific marketed drug inhibitor of
ALOX5, approved by the FDA as an anti-leukotriene oral
drug for the treatment of asthma.14 ,15 Its potential use as
anticancer drug has been recently addressed in clinical trials.
Thus, no safety issues related to oral administration of
Zileuton™ were reported in a clinical trial (Safety; phase 1)
in combination with Dasatinib (Sprycel®) (NCT02047149)
and with Imatinib Mesylate (Gleevec) (NCT01130688)
respectively, in patients with CML. Unfortunately, additional
randomized phase-II trails to study the efficacy of oral
Zileuton™ in cancer patients in combination with Standard-
of-Care treatments have not yield positive results, so far
(Clinical.Trials.gov). Most likely, the need of an intravenous
administration, the high hydrophobicity of the drug and its
high IC50, hamper its potential clinical use in the oncology
field. Here, we report on the anticancer and anti-metastatic
effects of new Zileuton™ -loaded polymeric micelles, using
in vivo breast CSCs models. Our data show significant
intratumoral reduction of CSCs in vivo, and also a strong
reduction of circulating cancer cells and CSCs in the blood
in these models.Methods
Microarray performance and validation
In total 8 RNA samples, comparing 2 technical replicates of
tdTomato positive (tdTomato+) and tdTomato negative (tdTomato−)
samples (corresponding to CSC and non-CSC) sorted from two
different cell lines (MCF7-ALDH1A1:tdTomato, MDA-MB-231-
ALDH1A1:tdTomato) (details in supplementary data) were ana-
lyzed bymicroarray. For this, 100 ng of totalRNAwas labeled using
LowInputQuick Amp Labeling kit v6.5 (Agilent 5190-2305)
following manufacturer instructions. The labeled cRNA was
hybridized to the Agilent SurePrint G3 Human gene expression
8×60K microarray (ID039494) according to the manufacturer's
protocol. The arrays were scanned on an Agilent G2565CA
microarray scanner at 100% PMT and 3 μm resolution. Raw data
were taken from the Feature Extraction output files and were
corrected for background noise using the normexp method.16 To
assure comparability across samples we used quantile
normalization.17 Differential expression analysis was carried out in
noncontrol probes with an empirical Bayes approach on linear
models (limma), applying a paired test.18 Results were corrected for
multiple testing according to the False Discovery Rate (FDR)
method.19 Obtained results were confirmed by qPCR and flow
cytometry (details in supplementary data). Clinical and expression
data of ALOX5 were obtained from The Cancer Genome Atlas
(TCGA) for breast invasive cancer collection, in order to correlate
these two features. Also, expression microarray data from the same
portal were used to evaluate ALOX5 overexpression with ovarian
serous cystadenocarcinoma, lung adenocarcinoma and colon
adenocarcinoma.
In vitro functional validation of free and encapsulated
Zileuton™
To validate efficacy of Zileuton™ in vitro, we performed i.)
Cell viability assay ii.) CSC resistance assay, and iii.) Cell
Transformation Assay (Anchorage-Independent Growth Assay)
(experimental details are in supplementary data).
Production and physicochemical characterization of PMs for
Zileuton™ delivery
PMs were prepared using the thin-film hydration technique
and characterized them by Dynamic Light Scattering (DLS)
(Malvern Instruments), Transmission Electron Microscopy
(TEM) and Cryo-Transmission Electron Microscopy (Cryo-
TEM) (details in supplementary data).
Furthermore; i.) Entrapment efficiency ii.) PMs stability, and
iii.) PMs internalization were evaluated (details in supplementary
data).
In vivo preclinical validation of PM-Zileuton™
Animal care was handled in accordance with the Guide for the
Care and Use of Laboratory Animals of the Vall d'Hebron
University Hospital Animal Facility, and the Animal Experi-
mentation Ethical Committee at the institution approved the
experimental procedures. All the in vivo studies were performed
by the ICTS “NANBIOSIS” of CIBER-BBN's In Vivo
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Preclinical Research (FVPR) area (CIBBIM-Nanomedicine,
Barcelona, Spain).
Orthotopic breast cancer models
MCF-7 and MDA-MB-231 breast cancer cells were orthoto-
pically inoculated into mammary fat pad (i.m.f.p) as previously
described.8,9 ,20 ,21 In detail, MDA-MB-231 cells and MCF-7
cells suspended with Matrigel (1:1) (BD Bioscience, Bedford,
MA, USA) were respectively implanted into the right abdominal
mammary fat pad (i.m.f.p.) of NOD-SCID mice (Supplementary
data). MCF-7 tumor bearing mice were also subcutaneously
injected with estrogen pellets (17β-Estradiol, 0.36 mg/pellet,
90 days release; Innovative Research of America, Sarasota FL,
USA). Further, 3 days before i.m.f.p. inoculation their drinking
water was supplemented with Baytril (Enrofloxacin) 0.08 mg/
mL as a preventive measure to minimize the side effects from
estradiol. Tumor growth was monitored twice a week by
conventional caliper measurements (D × d2/2, where D is the
major diameter and d the minor diameter).
Toxicity
Female athymic mice were treated intravenously (i.v.) with
1.5, 5 and 15 mg/kg (n = 5/dose) 3 times per week during
3 weeks. Body weight changes and animal welfare were
monitored along the assay. Animals were euthanized 1 h after
the last administration and blood and tissue samples collected
after gross necropsy.
Biodistribution
Ten mice were administered with a unique dose of PMs
labeled with fluorescent dye DIR at 0.8 mg DiR/kg by i.v.
administration route. Eight of these mice had i.m.f.p. MDA-MB-
231 tumors and 2 mice without tumor were also included in the
assay as a control to set the autofluorescence of the tissue. At 24,
44 and 72 h administration, tumor-accumulation and whole-
body biodistribution were measured non-invasively by DiR
fluorescence imaging (FLI) from the ventral and dorsal mouse
views, using the IVIS Spectrum (Perkin Elmer) imaging system
analyzed using Living Image® 4.5.2 software (PerkinElmer). In
addition, at 72 h post administration end time point, plasma,
tissue and tumor samples were collected, weighed and processed
for ex vivo imaging. The fluorescence signal in ex vivo images
was quantified in Radiant Efficiency units and referred to the
tissue weight following procedures previously described.8,20 ,21
Efficacy
In order to test the effects of PM-Zileuton™ in the tumor
growth and in the CSC population, orthotopic breast cancer
models were generated using freshly sorted tdTomato+ cells
(0.6 × 106 cells / mouse for the MCF-7 cell line and 0.1 × 106
cells/animal for the MDA-MB-231 cell line). Animals were then
treated with i.v. administration of PM-Zileuton™ (15 mg/kg), 3
times per week during 3 weeks. One day (MDA-MB-231) or
7 days (MCF-7) after the last administration animals were
euthanized and blood and tumor samples were collected for the
analysis of CSC content. To measure the extent of lung
metastasis ex vivo bioluminescent imaging (BLI) was
also performed using the IVIS Spectrum after administering150 mg/kg of luciferin to mice. Immediately after necropsy, lung
tissues were placed individually into separate wells containing
300 μg/mL of D-luciferin, and imaged and quantified using
Living Image® 4.5.2 software.21 Determination of circulating
tumor cells in the blood stream and the content of tdTomato+
cells within the tumor was performed by flow cytometry (details
in supplementary data). For this all injected cells expressed GFP
under CMV promotor. We analyzed all alive cells (Dapi−) that
emitted green fluorescence and quantified the ones which were
also tdTomato+ as CSC.Results:
ALOX5 is a breast CSC specific therapeutic target candidate
In order to design an effective anti-cancer therapy, we
analyzed transcriptome of CSCs sorted from two different CSC
fluorescent models; MDA-MB-231-ALDH1A1:tdTomato, a
basal-like breast cancer cell line highly aggressive and chemo-
resistant, and MCF7-ALDH1A1:tdTomato, a luminal breast
cancer cell line. Correlation-based clustering analysis of
microarray data revealed substantial disparity due to epithelial
(MCF7) and mesenchymal (MDA-MB-231) characteristics of
respective cell lines (Figure S1). Several mesenchymal markers
(e.g. VIM, CD44, SERPINE1/2, ESAM) were clearly over-
expressed in MDA-MB-231 cells and under-expressed in MCF7
cells. Contrarily, epithelial markers (e.g. CD24, KRT6B, KRT8,
KRT18, CDH1) were over-expressed in MCF7 cells and under-
represented in MDA-MB-231 cells25 (Figure S1). These
pronounced differences between cell line characteristics, partly
concealed the expected differences in reported CSC markers
(e.g. KLF5, DUSP6, ITGB2, ALDH1A1, SOX9/2, NOTCH2/4,
MUC16, GRHL2) comparing CSCs with non-CSCs1
(Figure S1). Nonetheless, we identified 75 up-regulated genes
(FC N 2) and 58 down-regulated genes (FC b 0.5) in CSCs
segregated from both, MCF7 and MDA MB 231 cell lines.
Several candidates were chosen for further confirmation based
on the uniformity of these increased levels found in CSCs in all
related samples and/or their relationship with CSC biology
(Figure 1, A).
In MDA-MB-231 CSCs, we confirmed increased mRNA
expression of; ALOX5 (Arachidonate 5-Lipoxygenase),
CMKLR1 (Chemokine like receptor 1), BST2 (Bone Marrow
Stromal Cell Antigen 2), SNAI1 (Snail family zinc finger 1). In
MCF7 CSCs, we confirmed increased expression of; TGFB2
(Transforming Growth Factor β 2), ALOX5, SPARC (Secreted
Protein, Acidic, Cysteine-Rich), PTPRE (Protein Tyrosine
Phosphatase, Receptor type, E), EGR4 (Early Growth Response
4), and SNAI1/2. Contrary to the microarray analysis, validation
through q-PCR did not prove any significant difference between
CSC and nonCSC regarding BST2 and LIPA in MCF7, and
EGR4, PTPRE, LIPA, TGFB2 and SNAIL2 genes in MDA-MB-
231 (Figure 1, B).
Only ALOX5 was significantly overexpressed in both, MDA-
MB-231 and MCF7 CSCs. Moreover, in silico analysis of data
from 590 patients with invasive breast cancer, revealed over-
expression of ALOX5 mRNA (FC N 2) in 83.6% of total cases
(Figure 1, C). However, no significant correlation with known
Figure 1. High-throughput microarray data from breast cancer cell lines.(A) Expression microarray analysis showing selected candidates for further validation by
qPCR. FC = fold-change. P value N0.05 shown in light red, P value b0.05 shown in light green. (B) Relative expression levels of selected candidates in CSC in
MCF-7 and MDA-MB-231 cell lines. Significant results with P value N0.05 are marked with *. Alox5 gene is upregulated in both cell lines. (C) ALOX5
expression levels for Breast Cancer, Ovarian Cancer, Lung Cancer and Colorectal Cancer according to The Cancer Genome Atlas (TCGA).(D) Alox5 expression
in CSCs in breast cancer cell lines. In order to obtain a CSCs enriched population, cells were grown as mammospheres in low attachment conditions without
FBS. (E) Increased expression of ALOX5 protein level was confirmed in MDA-MB-231 mammospheres. Significant results with P value ≤0.001 are marked
with ***.
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shown). Interestingly, clinical data also revealed over-expression
of ALOX5 mRNA in 80% of patients with ovarian cancer, 75%
of patients with lung cancer and in 50% of patients withcolorectal cancer. Increased ALOX5 mRNA expression was
further confirmed in a battery of triple negative breast cancer cell
lines (TNBC), BT549, MDA-MB-231, MDA-MB-468,
HCC1086, HCC1187, comparing normal cell culture conditions
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culture conditions (growing in non-attachment and in serum
depleted medium as mammospheres) (Figure 1, D). Moreover,
the increase of ALOX5 protein level was confirmed in MDA-
MB-231 CSC culture (Figure 1, E). Therefore, we have further
explored ALOX5 prospects as therapeutic target candidate to
develop anti-CSCs therapy.13
Significant antitumoral efficacy of Zileuton™ against CSCs
mammospheres
To validate the antitumoral effects against CSCs of inhibiting
ALOX5 we investigated the efficacy of a selective, FDA
approved ALOX5 inhibitor; Zileuton™. First, we determined the
half inhibitory concentration (IC50) of Zileuton™ in MDA-MB-
231 and MCF7 breast cancer cell lines. As expected, Zileuton™
was more effective against MCF7 than in more resistant
and aggressive MDA-MB-231 cell line. Of note IC50
[MCF7] = 292 μM, IC50 [MDA-MB-231] = 461 μM
(Figure S2). After, we determined the IC50 of Zileuton™ using
pure tdTomato+ CSCs subpopulation sorted from both cell lines.
The IC50 was determined in two different cell culture conditions.
On the one hand, in attachment conditions as normal cell culture
conditions and on the other, in low attachment conditions as
optimal conditions for CSCs culture. Interestingly, we observed
increased efficacy of Zileuton™ in CSCs from both cell lines
when CSCs were cultured in low attachment conditions; (IC50
[MCF7] = 29.4 μM, IC50 [MDA-MB-231] = 619 μM) com-
pared to normal attachment culture (IC50 [MCF7] = 499 μM,
IC50 [MDA-MB-231] = 852 μM) (Figure 2, A). Of note, we
could also determine that ALOX5 expression is increased when
CSCs are cultured as mammospheres (Figure 1, D, E).
Furthermore, Zileuton™ efficiently inhibited cellular growth
in soft agar (transformation assay), which is a hallmark of CSCs,
in a concentration dependent manner (Figure 2, B). Moreover, in
order to compare the effect of Zileuton™, with Paclitaxel (PTX)
and Abraxane™ (ABX), both drugs currently used in the
clinics,22 ,23 we evaluated the relative abundance of CSCs before
and after treatment, respectively. However, in order to mimic
chemotherapeutic cycles in a similar way than used as standard-
of-care, CSC in vitro models were treated with Zileuton™, PTX
and ABX for 72 h, and then cells left to recover in medium
without drugs during 48 additional hours. Even though in all
cases similar efficacy was reached, the relative abundance of
tdTomato+ CSCs increased significantly after PTX and ABX
treatment while remarkably, this was not observed after
Zileuton™ treatment, particularly in the resistant line, MDA-
MB-231 (Figure 2, C).
Production and physico-chemical characterization of pluronic-
F127 polymeric micelles loaded with Zileuton™
Zileuton™ is a highly hydrophobic compound that cannot be
administrated i.v. to reach the required therapeutic effect.
Because of this, we encapsulated Zileuton™ in the inner core
of polymeric micelles formed by amphiphilic polymer Pluronic®
F127, by thin-film hydration technique.24–26 The micelles
obtained (PM-Zileuton™) showed a mean diameter of 25 nm,
with a low polydispersity index (≤ 0.2) (Figure 3, A). These datawere confirmed by TEM and Cryo-TEM images, where it was
possible to observe micelles of small size in the region of 25 nm
with spherical morphology (Figure 3, B). DLS measurements
performed one and two months after the preparation of the
polymeric micelles confirmed their high stability at room
temperature, since their physico-chemical features did not
change over time (Figure S3, A). In addition, we tested the
stability of PM-Zileuton™ in bovine serum. Accordingly, no
aggregates appeared during 24 h in medium with FBS (50%)
(Figure S3, B). Further, we could also establish 0.075 μM
Zileuton™ stock as maximal encapsulatable dose, with up to
96% of encapsulation efficacy. These results were confirmed by
UPLC. Of note, it was impossible to further increase the
concentration of encapsulated Zileuton™, because at higher
concentration Zileuton™ precipitated and formed crystals during
the rehydration step.
Moreover, with the perspective to allow future clinical
studies, we also demonstrated stability and efficacy of
lyophilized PM-Zileuton™. Accordingly, no significant differ-
ences regarding size and in vitro efficacy were observed after the
lyophilization and rehydration processes (Figure 3, C).
Finally, internalization studies were also performed. Fluores-
cently tagged PMs were internalized as early as one minute after
its addition to cell culture in both cell lines (results of MCF7 cell
line not shown). After 10 min all cells have internalized the
tagged micelles and the intracellular amount of them followed to
increase afterwards, as it was perceived by a constant increase of
the fluorescence intensity (Figure 4, A). Interestingly, no
significant differences regarding PMs internalization were
observed between the subpopulations of CSCs and non-CSCs,
respectively (Figure 4, A). By confocal microscopy, we observed
lysosomal co-location of PMs tagged with 5-DTAF after 1 h and
also 24 h after internalization (Figure 4, B).
Strong inhibition of CSCs by PM-Zileuton™ in in vitro and in
vivo breast CSC models
Once polymeric micelles were produced and characterized, its
functional validation was assessed. First, a biodistribution study
was performed with DiR labeled PM™ in tumor bearing mice. In
vivo fluorescent imaging (FLI) clearly showed that micelles tend
to accumulate in the tumor area (mammary gland in the left
caudal area). Fluorescent signal was also observed in the
abdominal area, corresponding to the liver. Ex vivo imaging
and quantification of the fluorescent signal were performed 24
and 72 h post-injection showing the kinetics of the micelles
biodistribution and excretion (Figure 5). Data revealed that
micelles were being accumulated in the tumor with a relative
accumulation of 9.11% +/− 2.68% of total FLI signal per gram of
tissue at 24 h that was kept practically invariable at 72 h post-
administration (8.21% +/− 0.83% FLI/g). Liver and spleen also
retained the micelles in levels comparable to those in the tumor.
On the other hand, fluorescent signals in plasma, kidneys, lungs
and muscle showed clearly descended between 24 and 72 h,
indicating that micelles were cleared out by these organs.
Second, in vitro and in vivo efficacy was tested. Accordingly,
the IC50 of Zileuton™ was significantly decreased after its
encapsulation into PMs (IC50 [PM-Zileuton™] = 304 μM). Of
Figure 2. In vitro cell viability and transformation capacity of breast cancer cell lines and CSCs treated with Zileuton™.(A) Cell viability (MTT) assay for MCF7
and MDA-MB-231 CSCs treated with Zileuton™. Cells were grown in normal condition (NAP: normal attachment plates) and as mammospheres (LAP: low
attachment plates). IC50 corresponds to the half maximal inhibitory concentration and is indicated by a discontinuous red line. Cells without treatment represent
100% of viability. (B) Transformation capacity (anchorage independent growth) of MCF-7 and MDA-MB-231 CSCs treated with Zileuton™. (C) Content of
CSCs (tdTomato+) after treatment with Zileuton™ and ABX / PTX was quantified by flow cytometry in MCF-7 and MDA-MB-231 cell lines.
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Figure 3. Physico-chemical characterization and cell internalization of PM-Zileuton™.(A) DLS size distributions by intensity with Z-average and PdI values of
Polymeric micelles loaded with Zileuton™, and unloaded nanoconjugates. (B) Electron microscopy images; TEM technique / Cryo-TEM of polymeric micelles
loaded with Zileuton™. (C) Mean diameters (nm) of PM-Zileuton™ and unloaded micelles, measured by DLS before and after lyophilization and MDA-MB-
231 CSCs viability, measured before and after lyophilization.
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toxicity (Figure 6, A). Further, the transformation capacity of the
cells was significantly decreased by PM-Zileuton™ when
compared to free Zileuton™ (Figure 6, B). Moreover, because
CSCs growing as tumorspheres in low attachment are highly
resistant to common treatment (PTX, ABX), we wondered if
PM-Zileuton™ would be effective in these conditions. Remark-
ably, PM-Zileuton™ were able to reduce the viability of CSCs in
low attachment conditions, while no effect was seen for PTX and
ABX in these conditions (Figure 6, C). Moreover, we have
compared the viability of CSCs in normal growth condition or inlow attachment (mammospheres) after Zileuton™ treatment in
combination with Abraxane or Paclitaxel. Even though no
synergistic or additive effect was observed in combinatory
treatment, Zileuton™ PMs significantly compromised the
viability of MDA-MB-231 CSCs in all tested conditions (Figure
S4).
Next, to determine possible in vivo adverse side effects,
maximal feasible dose (MFD = 15 mg/kg) of PM-Zileuton™
was intravenously (i.v.) administrated into athymic mice. We did
not observe significant loss of weight of the animals or any
alterations in their overall well-being. Also, no macroscopic
Figure 4. Internalization of PM-Zileuton™ in breast cancer cells.(A) Over time course quantification of CSCs (tdTomato+; red) and non-CSCs (tdTomato−;
black) cellular uptake of fluorescently tagged PMs (PM-DTAF), reported as percentage of DTAF positive cells and relative increase of fluorescence intensity
over time. For each sample, at least 10,000 individual cells were collected and the mean fluorescence intensity was evaluated. (B) The internalization of PM-
Zileuton™ in breast MDA-MB-231 cancer cells was also observed by confocal microscopy 1 h and 24 h after internalization. Micelles were labeled with 5-
DTAF (green fluorescence), lysosomes were labeled with Lysotracker DND99 (in red) and DAPI was used to visualize nuclei (in blue). The co-location of
micelles and lysosomes was confirmed by fluorescence intensity plots over the illustrated dot line (24 h).
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Figure 5. In vivo biodistribution of PM in mice with breast cancer orthotopic tumors. In vivo and ex vivo BLI of intravenously administered DiR labeled PM™ in
athymic mice revealed that PM tended to accumulate in tumor tissues, being the clearance rate of nanoparticles in tumor lower than for other tissues. Fluorescent
signal was observed the tumor and in the abdominal area, corresponding to the liver. Ex vivo imaging and quantification of the fluorescent signal were performed
24 and 72 h post-injection showing the kinetics of the micelles biodistribution and excretion.
9P. Gener et al / Nanomedicine: Nanotechnology, Biology, and Medicine 24 (2020) 102106alterations were found by gross necropsy and further histological
evaluation (Figure S5).
Finally, we performed in vivo efficacy studies using
orthotopic breast cancer models. For this, CSCs sorted from
the MCF7 luminal breast cancer cell line and from the highly
aggressive MDA-MB-231 basal-like breast cancer cell line were
used. Cells were injected into mammary fat pad to ensure high
CSCs content in the growing tumors. Remarkably though, PM-
Zileuton™ significantly reduced almost by two-fold the content
of CSCc in the treated tumors compared to non-treated animals,
in both orthotopic models (Figure 7, A). CSCs decrease from
58% +/− 9% in vehicle-treated MDA-MB-231 tumors to 37.2%
+/− 4.7% in PM-Zileuton™ treated ones, and from 33.43% +/−
3.18% to 17.98% +/− 6.25% in MCF-7 models, respectively.
CSCs reduction was convoyed with the eradication of circulating
tumor cells (CTC) after PM-Zileuton™ treatment in a metastatic
MDA-MB-231 in vivo model (Figure 7, B). No CTC was
detected in MCF7 in vivomodel in any case (data not shown). As
expected, reduction of CTC in MDA-MB-231 model wasaccompanied by a significant reduction of metastasis detected
by BLI (Figure 7, C). In contrast, we have not observed
differences in tumor growth comparing group of animals treated
with vehicle or PM-Zileuton™ (Figure S6).Discussion
To identify CSC specific targets, in order to design effective
anti-CSCs treatment, we performed high throughput screening of
breast cancer CSCs. Our microarray results confirm that CSCs
derived from luminal MCF7 epithelial cell type are related to the
Epithelial to Mesenchymal Transition (EMT) phenotype as it
was previously suggested.27 We identified several EMT genes
(TGFB2, SNAI2 and SPARC) upregulated in CSCs isolated
from MCF7 cell line. Contrarily, these genes were not up-
regulated in MDA-MB-231 luminal cell line, most likely,
because of the high basal expression of EMT genes in this cell
line. In this context, overall data suggest that the EMT pathway
Figure 6. In vitro cell viability of breast cancer cell lines treated with PM-Zileuton™.(A) Cell viability of MDA-MB-231 cell line treated with Zileuton™ and
PM-Zileuton™ and with corresponding mass of empty nanoparticles has been determined. IC50 corresponds to the half maximal inhibitory concentration and is
indicated by a discontinuous red line. Cells without treatment represent 100% of viability.(B) Cell transformation assay of MDA-MB-231 treated with
Zileuton™ and PM-Zileuton™ has been determined. (C) Cells were grown in normal condition (NAP: normal attachment plates) and as mammospheres (LAP:
low attachment plates) and treated with Zileuton™ and PM-Zileuton™, PTX or ABX. IC50 corresponds to the half maximal inhibitory concentration and is
indicated by a discontinuous red line. Cells without treatment represent 100% of viability.
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breast tumors.10,27 ,28 Future high throughput screening might
reveal additional CSCs target candidates, because the disparity
between the two analyzed cell lines can veil some less
pronounced differences in gene expression when comparing
CSCs versus non-CSCs. Nonetheless, we have found and
corroborated ALOX5 overexpression in CSC subpopulations
from these two highly distinctive breast cancer cell lines.
It has been reported that Alox5 deficiency resulted in a
significant reduction of Leukemic Stem Cells (LSCs) in bone
marrow, and thus largely prolonged survival of CML mice.29Importantly, there was no significant influence of Alox5
deficiency on normal hematopoietic stem cells (HSCs) or on
the induction of lymphoid leukemia by BCR-ABL.12 Besides,
ALOX5 is largely known as an oncogene in solid tumors, e.g.
prostate cancer and pancreas cancer.30–32 On the molecular level,
the inhibition of Alox5 was linked to upregulation of the tumor
suppressor gene, Msr1, and consequent regulation of PI3K-
AKT-GSK-3β and β-Catenin pathways (19). In this study we
have further confirmed ALOX5 overexpression in a large battery
of TNBC breast cancer cell lines cultured as mammospheres, in
order to mimic CSCs growth. Further, clinical data confirmed its
Figure 7. Effects of PM-Zileuton™ on CSC and CTC in vivo.Orthotopic breast cancer models were generated using tdTomato+ MDA-MB-231 cells. A
posteriori, animals were then treated with i.v. administration of PM-Zileuton™ (15 mg/kg), 3 times per week during 3 weeks and blood and tumor samples were
collected for the analysis of CSC content. Also lung metastasis ex vivo bioluminescent imaging (BLI) was performed using the IVIS Spectrum after
administering 150 mg/kg of luciferin to mice. (A) In vivo effects of PM-Zileuton™ in CSC content in mice tumors; (B) In vivo effects of PM-Zileuton™ in CTC
and CSC in the blood stream in tumor bearing mice; (C) In vivo effects of PM-Zileuton™ in lung metastasis.
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overexpression was not significantly confined to any clinical
feature, or any specific cancer stage. Our data suggest a potential
role of Alox5 in CSC homeostasis in tumorigenesis.
Fortunately, Zileuton™, a specific inhibitor of ALOX5, is
approved by the FDA for treating asthma.14,15 Studies with
Zileuton™ as anti-cancer agent are undergoing. Zileuton™
(Zyflo®) is in clinical trial (phase 1) in combination with Dasatinib
(Sprycel®) (NCT02047149) and with Imatinib Mesylate (Gleevec)
(NCT01130688), respectively, in patients with CML. Zileuton™
(Zyflo®) is also being investigated for lung cancer chemoprevention(currently in phase 2), with the aim to prevent lung cancer in patients
with bronchial dysplasia (NCT00056004).
We have confirmed the effectiveness of its inhibition against
CSCs population in various in vitro assays. Interestingly,
Zileuton™ shows much better IC50 score in low attachment
conditions, where just CSCs can proliferate because of their
capacity to survive in non-adherent conditions, a clear feature of
stemness. Of note, ALOX5 expression is also significantly
increased during these conditions. This might suggest a potential
functional role of Alox5 in non-attached cells where its inhibition
causes greater effect in CSC than in normal adherent culture
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CSCs by using Zileuton™. In agreement to this, we also
confirmed the anti-CSCs effects of Zileuton™ by using
transformation assays in soft agar, one of the hallmarks of CSCs.
Nonetheless, Zileuton™ efficacy dose is considerably
high in terms of future clinical use. Moreover, because of its
highly hydrophobicity, Zileuton™ also needs to be solubi-
lized for i.v. administration. Here, we used versatile
amphiphilic polymer, Pluronic® F127 to encapsulate Zileu-
ton™. It is an FDA approved biodegradable polymer with
known characteristics and proved advantages for synthesis of
drug delivery systems, and its usefulness has been demon-
strated previously in various drug delivery systems.10 ,11 , 24
, 25 We employed a thin-film hydration technique to
synthesize polymeric micelles with Zileuton™ encapsulated
in their hydrophobic inner core. Importantly, due to their
stability and the possibility of lyophilization, PM-Zileuton™
are easily scalable for future Good Manufacturing Practice
(GMP) production in order to facilitate posterior translation
and clinical implementation.
Furthermore, we do not observe any toxicity in vivo when
using the maximal feasible dose (MFD) (15 kg/mg). This dose
was calculated based on maximal encapsulation dose and
volume that can be injected per mice. The biodistribution assay
performed with DiR labeled PM in tumor bearing mice shows
very good accumulation of PM within the tumor. On the other
hand, fluorescent signals in plasma, kidneys, lungs and muscle
clearly diminish between 24 and 72 h, indicating that micelles
are cleared out from these organs.
As expected, CSCs population is significantly decreased
in both CSCs orthotopic models after PM-Zileuton™
treatment and importantly, in the highly metastatic MDA-
MB-231cell line we observe a complete eradication of CTCs
in the blood stream. Because CTCs and particularly, the
fraction of CSCs within them are thought to be responsible
for metastatic spread, we hypothesized an effect of PM-
Zileuton™ treatment on tumor dissemination. Our data
confirms that metastatic foci from MDA-MB-231 in our
orthotopic in vivo model are significantly smaller after PM-
Zileuton™ treatment suggesting a clear potential use of PM-
Zileuton™ as anti-metastatic agent. This further suggests that
PM-Zileuton™ could show synergistic efficacy in combina-
tion with current cytotoxic treatments, which might be highly
relevant to improve current Standard-of-Care therapies. Of
note, therapies seeking for the elimination of CSCs in order
to prevent tumor growth and the appearance of metastases
have an important limitation. Eliminated CSCs are constantly
replaced by new cells with stemness phenotype by a process
of de-differentiation (so call reversion) of non-CSC in order
to ensure tumor survival and propagation after treatment. As
a result, CSCs specific treatments have just limited clinical
success, so far. We thus propose to evaluate the combination
of PM-Zileuton™ and Standard-of-Care treatments (i.e.,
Abraxane™ (Nab-PTX) nanoparticles), used in the clinical
setting. This cocktail may represent an ideal option to
abrogate tumor and metastatic growth, along with avoiding
CSC reversion.Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.nano.2019.102106.References
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